Characterization of the Monomeric and Dimeric Forms of Latent and Active Matrix Metalloproteinase-9. Differential Rates for Activation by Stromelysin 1
Overview
Authors
Affiliations
Matrix metalloproteinase-9 (MMP-9) is a member of the MMP family that has been associated with degradation of the extracellular matrix in normal and pathological conditions. A unique characteristic of MMP-9 is its ability to exist in a monomeric and a disulfide-bonded dimeric form. However, there exists a paucity of information on the properties of the latent (pro-MMP-9) and active MMP-9 dimer. Here we report the purification to homogeneity of the monomer and dimer forms of pro-MMP-9 and the characterization of their biochemical properties and interactions with tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. Gel filtration and surface plasmon resonance analyses demonstrated that the pro-MMP-9 monomeric and dimeric forms bind TIMP-1 with similar affinities. In contrast, TIMP-2 binds only to the active forms. After activation, the two enzyme forms exhibited equal catalytic competence in the turnover of a synthetic peptide substrate with comparable kinetic parameters for the onset of inhibition with TIMPs and for dissociation of the inhibited complexes. Kinetic analyses of the activation of monomeric and dimeric pro-MMP-9 by stromelysin 1 revealed K(m) values in the nanomolar range and relative low k(cat) values (1.9 x 10(-3) and 4.1 x 10(-4) s(-1), for the monomer and dimer, respectively) consistent with a faster rate (1 order of magnitude) of activation of the monomeric form by stromelysin 1. This suggests that the rate-limiting event in the activation of pro-MMP-9 may be a requisite slow unfolding of pro-MMP-9 near the site of the hydrolytic cleavage by stromelysin 1.
Xiao J, Huang J, Yolken R Brain Behav Immun Health. 2024; 36:100728.
PMID: 38323226 PMC: 10844038. DOI: 10.1016/j.bbih.2024.100728.
Metformin Directly Binds to MMP-9 to Improve Plaque Stability.
Chen X, Wang S, Xu W, Zhao M, Zhang Y, Xiao H J Cardiovasc Dev Dis. 2023; 10(2).
PMID: 36826550 PMC: 9962015. DOI: 10.3390/jcdd10020054.
Palladini G, Cagna M, Di Pasqua L, Adorini L, Croce A, Perlini S Pharmaceuticals (Basel). 2022; 15(5).
PMID: 35631351 PMC: 9145209. DOI: 10.3390/ph15050524.
MMP9: A Tough Target for Targeted Therapy for Cancer.
Augoff K, Hryniewicz-Jankowska A, Tabola R, Stach K Cancers (Basel). 2022; 14(7).
PMID: 35406619 PMC: 8998077. DOI: 10.3390/cancers14071847.
Khaliq S, Umair Z, Baek M, Chon S, Yoon M Front Cell Dev Biol. 2022; 10:800181.
PMID: 35127683 PMC: 8814361. DOI: 10.3389/fcell.2022.800181.